Skip to main content
. 2016 Feb 17;11(2):e0149265. doi: 10.1371/journal.pone.0149265

Fig 2. Effects of the TRF and ATF treatments on cell viability and proliferation.

Fig 2

Dose-response curve of TRF (a) and ATF (b) treatments (24 h) in young and senescent myoblasts (n = 9). The prolonged treatments of TRF and ATF (48 h) at optimal dose were unlikely to further improve cell viability in senescent myoblasts (c). Therefore, 24 h treatment was used in subsequent experiment. Comparison of cell viability between myoblasts from donor 1, a 17 year-old, female Caucasian and donor 2, a 16 year-old male Caucasian (d). There were no significant different observed between the two cell lines in response to both TRF and ATF treatments based on the viability assessment. Post-hoc Dunnett T3 test for (a) and (b). *p<0.05 significantly different compared to untreated young myoblasts, #p<0.05 significantly different compared to untreated senescent myoblasts, §p<0.05 significantly different compared to TRF-treated senescent myoblasts. The data are presented as the means ± SD.